Epcoritamab (Epkinly®/Tepkinly®): A Comprehensive Clinical and Pharmacological Monograph

I. Executive Summary

Epcoritamab represents a pivotal advancement in the therapeutic armamentarium for relapsed or refractory (R/R) B-cell malignancies. As a subcutaneously administered, off-the-shelf, T-cell engaging bispecific antibody, it offers a novel mechanism of action that has demonstrated profound and durable clinical activity in heavily pre-treated patient populations. This report provides a comprehensive analysis of epcoritamab, synthesizing data from pivotal clinical trials, regulatory filings, and pharmacological studies to delineate its profile and strategic position in oncology.

The core clinical value of epcoritamab is evidenced by its high response rates in patient populations with significant unmet needs. In the pivotal EPCORE NHL-1 trial, epcoritamab monotherapy induced an overall response rate (ORR) of 61-63% and a complete response (CR) rate of 38-41% in patients with R/R diffuse large B-cell lymphoma (DLBCL), including those who had previously failed CAR T-cell therapy. Long-term follow-up has confirmed the durability of these responses, with a median duration of complete response (mDoCR) extending to 36.1 months, suggesting a potential for long-term disease control in a substantial subset of patients. Similarly, in R/R follicular lymphoma (FL), epcoritamab achieved an ORR of 82% and a CR rate of 60%, leading to its accelerated approval for this indication.

The safety profile of epcoritamab is characterized by two primary mechanism-based toxicities, Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), for which the drug carries a boxed warning. However, these events have proven to be largely predictable, occurring predominantly during the initial treatment cycle, and are manageable with a structured step-up dosing schedule, mandatory premedication, and supportive care. Clinical development has successfully optimized these mitigation strategies, particularly for the FL indication, enhancing the therapy's benefit-risk profile.

Developed collaboratively by Genmab and AbbVie using Genmab's proprietary DuoBody® technology, epcoritamab has secured regulatory approvals in major global markets, including the United States (as Epkinly®) and the European Union (as Tepkinly®). Its subcutaneous administration offers a significant advantage in practice efficiency and patient convenience over intravenous alternatives. The ongoing and extensive clinical development program, which is exploring epcoritamab in combination with standard-of-care agents and in earlier lines of therapy, underscores the strategic intent to establish it as a core therapy across a spectrum of B-cell cancers. This report details the evidence supporting epcoritamab's current role and its potential to reshape future treatment paradigms for lymphoma.

II. Introduction and Drug Profile

Epcoritamab is a novel immunotherapy that has emerged as a significant treatment option for patients with certain types of B-cell lymphomas. Its development and approval mark a key milestone in the application of bispecific antibody technology to hematologic malignancies.

2.1. Development and Formulation

The development of epcoritamab is the result of a strategic collaboration between Genmab A/S, a Danish biotechnology firm renowned for its antibody expertise, and AbbVie, a major American biopharmaceutical company with a global commercial footprint.[1] This partnership, part of a broader oncology collaboration, combines Genmab's innovative technological platforms with AbbVie's extensive clinical development and commercialization capabilities.[3]

The molecular foundation of epcoritamab lies in Genmab's proprietary DuoBody® technology platform.[2] This platform enables the efficient and stable generation of bispecific antibodies that can simultaneously bind to two different targets. Epcoritamab is the fourth approved medicine created using this validated platform, a testament to the technology's maturity and reliability in producing clinically viable therapeutics.[3] The use of a proven system likely de-risked and accelerated the early development pathway, allowing for the creation of an antibody with predictable binding characteristics and functional activity.

Epcoritamab is classified as a biotech drug (DrugBank ID: DB16672) and is produced as a humanized immunoglobulin G1 (IgG1) bispecific antibody through recombinant DNA technology in Chinese Hamster Ovary (CHO) cell lines.[4]

2.2. Physicochemical and Drug Identifiers

Epcoritamab is identified by a consistent set of names and codes across clinical and regulatory domains.

• Name: The International Nonproprietary Name (INN) is Epcoritamab.[4] In the United States, the official nonproprietary name includes a four-letter suffix, epcoritamab-bysp, which is intended to distinguish it from other biological products.[7]
• Brand Names: The drug is marketed under two primary brand names depending on the region: Epkinly® in the United States and Japan, and Tepkinly® in the European Union.[1]
• Synonyms and Development Codes: During its development, epcoritamab was referred to by the code GEN3013. It is also known by the technological descriptor DuoBody®-CD3xCD20.[4]
• Regulatory and Chemical Identifiers:
• DrugBank ID: DB16672
• CAS Number: 2134641-34-0 [1]
• ATC Code: L01FX27 (Antineoplastic agents, Monoclonal antibodies and antibody drug conjugates, Other monoclonal antibodies).[1]
• Molecular Formula: C6471​H9999​N1735​O2007​S44​.[1]
• Molar Mass: Approximately 145624.95 g·mol−1.[1]

III. Clinical Pharmacology

The clinical activity of epcoritamab is rooted in its unique bispecific mechanism of action and its well-characterized pharmacokinetic profile. These pharmacological properties collectively define its efficacy, safety, and dosing regimen.

3.1. Mechanism of Action: Bridging T-Cells and Malignant B-Cells

Epcoritamab functions as a T-cell engaging bispecific antibody, a class of immunotherapy designed to harness the patient's own immune system to fight cancer.[8] Its mechanism is predicated on its ability to simultaneously bind to two distinct protein targets.[6]

One arm of the antibody binds to the CD3 epsilon (CD3E) subunit, a component of the T-cell receptor (TCR) complex found on the surface of cytotoxic T-cells.[1] The other arm binds to the

CD20 antigen, a protein highly expressed on the surface of both normal and malignant B-cells, which are the cancerous cells in B-cell lymphomas.[8]

By co-engaging these two targets, epcoritamab physically bridges a T-cell and a cancerous B-cell, forcing them into close proximity and creating a structure known as an immunological synapse.[8] This engineered interaction bypasses the conventional need for T-cell recognition of cancer antigens via the major histocompatibility complex (MHC). The binding to CD3 triggers potent T-cell activation, proliferation, and expansion.[6] The activated T-cells then release proinflammatory cytokines (such as interleukin-6) and cytotoxic granules containing proteins like perforin and granzymes directly toward the tethered B-cell.[6] This targeted delivery of cytotoxic molecules results in the efficient, T-cell-mediated lysis and elimination of the CD20-positive tumor cells.[5]

A critical feature of this mechanism is its effectiveness in patients who have been previously treated with other anti-CD20 therapies, such as rituximab. Studies have shown that epcoritamab induces potent anti-tumor activity against malignant B-cells irrespective of prior exposure to CD20 monoclonal antibodies, suggesting it can overcome certain mechanisms of resistance to conventional antibody therapies.[1]

3.2. Pharmacokinetics (PK)

The pharmacokinetic profile of epcoritamab is defined by its subcutaneous administration, slow absorption, large volume of distribution, and long elimination half-life, which collectively influence its dosing schedule and clinical behavior.

• Absorption: Epcoritamab is administered exclusively via subcutaneous (SC) injection.[1] Following SC administration, absorption is slow. The median time to reach maximum plasma concentration ( Tmax​) is approximately 4 days after the first full 48 mg dose in Cycle 1. With continued dosing, this shortens to a median of 2.3 days by the end of the weekly dosing regimen in Cycle 3, suggesting an acceleration in absorption as treatment progresses.[6]
• Distribution: The drug distributes widely throughout the body. The geometric mean central volume of distribution is 8.27 L, while the apparent total volume of distribution at steady state is significantly larger at 25.6 L.[6] It is unknown whether epcoritamab crosses the blood-brain barrier.[6]
• Metabolism: As a large protein-based therapeutic, epcoritamab is not metabolized by the hepatic cytochrome P450 (CYP) enzyme system. Instead, it is expected to be degraded into smaller peptides and amino acids through general, non-specific catabolic pathways, similar to endogenous immunoglobulins.[6]
• Elimination: The elimination of epcoritamab is nonlinear and is characterized by saturable target-mediated drug disposition (TMDD).[6] This means that at lower concentrations, a significant portion of the drug is cleared by binding to its targets (CD20 on B-cells), while at higher, therapeutic concentrations, this pathway becomes saturated and linear clearance pathways dominate. The apparent total clearance at the 48 mg dose level is approximately 0.53 L/day.[6] The terminal elimination half-life is long, estimated to be between 22 and 25 days.[6] This long half-life is a key determinant of the dosing schedule, as it allows for the transition from weekly to bi-weekly and ultimately monthly administration in later cycles while maintaining therapeutic drug concentrations.
• Drug Interactions: Epcoritamab does not directly interact with CYP enzymes. However, the release of proinflammatory cytokines induced by its mechanism of action can cause transient suppression of CYP450 enzyme activity. This can lead to increased plasma concentrations of co-administered drugs that are CYP substrates, particularly those with a narrow therapeutic index such as warfarin or cyclosporine. Close monitoring of such substrates is recommended, especially in the period following the first full dose of epcoritamab.[12]

3.3. Population Pharmacokinetics and Special Populations

A formal population pharmacokinetic analysis was conducted using data from 327 patients enrolled in the EPCORE NHL-1 and EPCORE NHL-3 trials, which evaluated a wide range of subcutaneous doses.[16] The analysis identified age and body weight as statistically significant covariates influencing epcoritamab pharmacokinetics. However, after adjusting for the effect of body weight, other factors such as age, sex, race, mild-to-moderate renal impairment, and mild hepatic impairment were not found to have a clinically meaningful impact on drug exposure.[16] Based on these findings, no specific dose adjustments are recommended for patients based on these demographic or organ function characteristics.[16]

3.4. Immunogenicity

The potential for the body to generate an immune response against a therapeutic antibody is known as immunogenicity. For epcoritamab, the risk appears to be low. In a pooled analysis of patients treated with the approved dosing regimen, only 2.6% (4 of 156 evaluable patients) developed anti-drug antibodies (ADAs).[16] Importantly, the development of these ADAs did not have a discernible effect on the pharmacokinetic profile of epcoritamab, suggesting they are not clinically significant.[16]

Table 1: Summary of Epcoritamab Pharmacokinetic Parameters

Parameter	Value	Source Snippet(s)
Route of Administration	Subcutaneous	1
Tmax (First Full Dose, 48 mg)	~4 days	6
Tmax (End of Cycle 3)	~2.3 days	6
Volume of Distribution (Steady State)	25.6 L	6
Elimination Pathway	Catabolism, Target-Mediated Drug Disposition	6
Apparent Total Clearance	0.53 L/day	6
Terminal Half-life	22 - 25 days	13
Immunogenicity (ADA Rate)	2.6%	16

IV. Clinical Efficacy in Relapsed/Refractory Large B-Cell Lymphoma (DLBCL)

The approval of epcoritamab for DLBCL was based on its robust and durable efficacy demonstrated in a heavily pre-treated patient population within the pivotal EPCORE NHL-1 trial. The long-term follow-up data from this study have been particularly informative, revealing the potential for lasting remissions.

4.1. Pivotal Trial Evidence: The EPCORE NHL-1 Study (DLBCL Cohort)

The clinical evidence supporting epcoritamab's use in DLBCL stems primarily from the DLBCL cohort of the EPCORE NHL-1 trial (NCT03625037).[1] This was a large, open-label, multi-cohort, single-arm Phase 1/2 study designed to evaluate the safety and efficacy of epcoritamab monotherapy. The efficacy population for the DLBCL indication comprised 148 to 157 patients with R/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBCL).[1]

The patient population enrolled was characteristic of a setting with high unmet medical need. These were patients whose disease had progressed despite multiple prior treatments. The median number of prior lines of therapy was three, with some patients having received as many as eleven.[19] The cohort included a significant proportion of patients with poor prognostic features: 18% had undergone a prior autologous stem cell transplant (ASCT), and a remarkable 39% had received prior CAR T-cell therapy.[3] Furthermore, 82% of patients had disease that was refractory to their most recent line of therapy, including 29% who were refractory to CAR T-cell therapy, and 61% had primary refractory disease, underscoring the challenging nature of this population.[3]

4.2. Efficacy Outcomes and Durability of Response (Multiple Follow-up Points)

The efficacy of epcoritamab has been consistently demonstrated across multiple data readouts with increasing follow-up duration, highlighting the durability of the responses.

• Initial Approval Data (Median follow-up ~10.7 months): The data that supported the initial accelerated approval showed impressive activity. The overall response rate (ORR) was 61-63%, with a complete response (CR) rate of 38-40%.[3] The median duration of response (mDoR) was reported as 15.5 months.[3]
• Long-Term Follow-up (Median follow-up 25.1 months): As follow-up extended, the response rates remained stable, with an ORR of 63.1% and a CR rate of 40.1%.[20] The durability of these responses became more apparent, with estimated 24-month progression-free survival (PFS) and overall survival (OS) rates of 27.8% and 44.6%, respectively.[20]
• Extended 3-Year Follow-up (Median follow-up 37.1 months): With nearly three years of follow-up, the investigator-assessed ORR and CR rates were 59% and 41%, respectively.[21] The median duration of response (mDoR) extended to 20.8 months, and the median overall survival (mOS) for the entire cohort was 18.5 months.[19]

4.3. Depth and Durability of Complete Response: A Key Predictor of Outcome

While the overall response rates are compelling, a deeper analysis of the data reveals that achieving a complete response with epcoritamab is a transformative event for patients, correlating strongly with long-term survival and durable disease control. This bifurcation in outcomes is a critical finding. For the ~40% of patients who achieve a CR, the prognosis shifts dramatically from one of expected short-term survival to one of potential cure.

The stability of these complete responses is a standout feature of the therapy. At the 25.1-month follow-up, an estimated 64.2% of patients who achieved a CR were still in remission at the 24-month mark.[20] This durability was further confirmed with longer follow-up; the median duration of complete response (mDoCR) reached an impressive 36.1 months.[19]

This durable remission translates directly into improved survival. For the subset of patients who achieved a CR, the estimated 24-month PFS was 65.1% and the OS rate was 78.2%.[20] At the 3-year follow-up, the median PFS for complete responders was 37.3 months, and the median OS had not yet been reached, with an estimated 63% of these patients still alive at 36 months.[21] A novel landmark analysis focusing on the 32 patients who were in CR at the 2-year mark found that approximately 96% of them remained in CR at 3 years, with both mPFS and mOS not reached for this highly favorable subgroup.[23] This suggests that once a deep and lasting remission is established with epcoritamab, it is highly likely to be maintained long-term, a remarkable outcome for an off-the-shelf therapy in this heavily pretreated setting.

4.4. Minimal Residual Disease (MRD) Negativity

The depth of response was further assessed by measuring minimal residual disease (MRD), a highly sensitive measure of remaining cancer cells. Among 119 evaluable patients, 45.4% achieved MRD negativity.[20] Achieving MRD-negative status was a strong predictor of superior outcomes. A landmark analysis at Cycle 3, Day 1 showed that the 36-month PFS and OS rates were 52% and 55%, respectively, for patients who were MRD-negative, compared to just 18% and 30% for those who remained MRD-positive.[21] This underscores that epcoritamab can induce deep molecular remissions that correlate with long-term clinical benefit.

Table 2: Efficacy of Epcoritamab in R/R DLBCL (EPCORE NHL-1) - Evolution with Follow-Up

Efficacy Endpoint	Initial Approval Data (Median F/U ~10 mo)	25-Month F/U Data	3-Year F/U Data	Source Snippet(s)
ORR	61-63%	63.1%	59% (INV)	12
CR Rate	38-40%	40.1%	41% (INV)	3
mDoR	15.5 months	Not Reported	20.8 months	3
mOS (All Patients)	Not Mature	18.5 months	18.5 months	21
mDoCR	Not Mature	Not Reported	36.1 months	19
mOS (in CR Responders)	Not Mature	Not Reached	Not Reached	20
24-mo OS (in CR Responders)	Not Applicable	78.2%	Not Reported	20

INV = Investigator Assessed

V. Clinical Efficacy in Relapsed/Refractory Follicular Lymphoma (FL)

Building on its success in aggressive lymphomas, epcoritamab has also demonstrated compelling efficacy in relapsed/refractory follicular lymphoma (FL), a more indolent but often incurable form of non-Hodgkin lymphoma. Its performance in this setting led to a rapid expansion of its approved indications.

5.1. Pivotal Trial Evidence: The EPCORE NHL-1 Study (FL Cohort)

The basis for epcoritamab's approval in FL was a dedicated cohort within the same EPCORE NHL-1 phase 1/2 trial (NCT03625037).[1] This analysis included 127 adult patients with R/R FL who had failed at least two prior lines of systemic therapy.[1] Similar to the DLBCL cohort, this was a difficult-to-treat population, with patients having received a median of three prior therapies. A substantial proportion (70%) had double refractory disease, meaning their cancer was resistant to both an anti-CD20 antibody and an alkylating agent, leaving them with limited effective treatment options.[2]

5.2. Efficacy Outcomes

The efficacy results in the FL cohort were striking and formed the basis for the FDA's accelerated approval.[2] The therapy induced high, rapid, and durable responses.

• Response Rates: The study reported exceptionally high response rates.
• Overall Response Rate (ORR): 82% (95% CI 74.1, 88.2) of patients responded to the treatment.[2]
• Complete Response (CR) Rate: 60-63% of patients achieved a complete response, indicating the eradication of all detectable cancer.[27]
• Rapidity and Duration of Response: A key feature of the treatment was the speed at which responses occurred and their subsequent durability.
• Median Time to Response: The median time to any response (partial or complete) was just 1.4 months.[29]
• Median Time to CR: The median time to achieve a complete response was similarly rapid, at 1.5 months.[29]
• Median Duration of Response (mDoR): The durability of these responses was notable. With a median follow-up of 14.8 months among responders, the median DoR was not reached, signifying that more than half of the responding patients had not progressed at the time of analysis.[27] The Kaplan-Meier estimate for the rate of DoR at 12 months was 68.4%.[27]
• Minimal Residual Disease (MRD) Negativity: The depth of response was confirmed at the molecular level, with 67% of patients achieving MRD negativity, a strong indicator of profound disease clearance.[2]

5.3. Impact of CRS Mitigation Strategies on Efficacy

A crucial aspect of the FL clinical development was the evaluation of an optimized dosing schedule designed to improve the drug's safety profile. Follicular lymphoma is typically a more indolent disease than DLBCL, making the benefit-risk calculation different, with a lower tolerance for treatment-related toxicity. To address this, the trial investigated a modified "3-step-up" dosing regimen in Cycle 1 (0.16 mg, 0.8 mg, 3 mg, followed by the first full 48 mg dose) specifically for the purpose of mitigating CRS.[27]

This strategy was evaluated in a separate dose optimization cohort of 86 patients. The results confirmed that this approach was successful in improving safety without compromising efficacy. The response rates and clinical outcomes in the cohort that received the 3-step-up regimen were similar to those seen in the primary efficacy population that received a 2-step-up regimen.[27] This finding was critical, as it demonstrated that the primary safety concern could be proactively and effectively managed through rational dose scheduling. This successful uncoupling of safety optimization from efficacy confirmed that the potent therapeutic benefit of epcoritamab could be delivered with a better safety margin, making it a highly attractive option for the FL patient population.

VI. Safety and Tolerability Profile

The safety profile of epcoritamab is well-defined and is dominated by on-target, mechanism-based toxicities. While the drug carries serious warnings, these adverse events are generally predictable and manageable with established protocols, a fact that has been refined and confirmed through clinical trial experience.

6.1. Boxed Warnings: A Comprehensive Review

The U.S. Food and Drug Administration (FDA) prescribing information for Epkinly includes a boxed warning highlighting the risk of two potentially severe adverse reactions: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[1]

6.1.1. Cytokine Release Syndrome (CRS)

CRS is the most common significant adverse reaction associated with epcoritamab, stemming directly from the T-cell activation induced by its mechanism of action.[3]

• Incidence and Severity: CRS occurs in approximately 51% of patients with DLBCL and 66% of patients with FL.[19] The vast majority of these events are low grade. In DLBCL, 37% of patients experience Grade 1 CRS and 17% experience Grade 2, with Grade 3 events being infrequent (around 2.5%).[19] The optimized dosing in FL further mitigates severity, with events being 40% Grade 1, 25% Grade 2, and only 2% Grade 3.[29] Life-threatening or fatal CRS is rare but has been reported.[3]
• Timing and Predictability: A key feature of epcoritamab-induced CRS is its predictability. The onset of symptoms is not random; most events occur early in the treatment course, typically following the administration of the first full 48 mg dose on Day 15 of Cycle 1.[13] The incidence of CRS is substantially lower with subsequent doses.[13] This predictable timing allows for targeted monitoring and intervention.
• Clinical Manifestations: The signs and symptoms of CRS are driven by a surge in proinflammatory cytokines and include fever (pyrexia), chills, headache, hypotension (low blood pressure), hypoxia (low oxygen levels), and tachycardia (fast heart rate).[3]
• Management and Resolution: CRS is a manageable and transient event. The median duration of symptoms is 2 to 3 days, and events resolve in the vast majority of patients.[6] The cornerstone of management is the proactive mitigation strategy built into the administration protocol, which includes a gradual step-up dosing schedule and mandatory premedication with corticosteroids, antihistamines, and antipyretics.[6] For emergent CRS, management involves supportive care (e.g., fluids, oxygen) and, for Grade 2 or higher events, the use of the IL-6 receptor antagonist tocilizumab and/or increased doses of corticosteroids.[17]

6.1.2. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS is a less common but potentially more severe neurological toxicity also associated with T-cell engaging therapies.

• Incidence and Severity: ICANS is reported in approximately 6% of both DLBCL and FL patients treated with epcoritamab.[34] As with CRS, most events are low grade (Grade 1 or 2). However, severe and fatal (Grade 5) ICANS have occurred, albeit rarely (e.g., 0.6% fatal rate in the DLBCL trial).[3]
• Timing: The onset of ICANS typically occurs during the first treatment cycle, with a median time to onset of around 17 days in one report.[6] However, it can have a delayed onset and may occur concurrently with CRS, after CRS has resolved, or in the complete absence of CRS.[3]
• Clinical Manifestations: Neurological symptoms can be varied and may include confusion, disorientation, lethargy, tremor, difficulty speaking (aphasia) or writing (dysgraphia), motor weakness, and in severe cases, seizures or cerebral edema.[6]
• Management: Management requires vigilant monitoring for any neurological changes. Patients are explicitly warned not to drive or operate heavy or dangerous machinery if they experience symptoms like dizziness, confusion, or tremors.[33] Treatment involves supportive care and the administration of corticosteroids for any event above Grade 1. Hospitalization after the first full dose in the DLBCL protocol is mandated in part to monitor for the emergence of ICANS.[32]

6.2. Other Clinically Significant Adverse Reactions

Beyond the boxed warnings, several other adverse reactions warrant clinical attention.

• Infections: Due to its mechanism involving B-cell depletion and immune modulation, epcoritamab can increase the risk of serious or fatal infections. Infections were observed in 45% of LBCL patients, with Grade 3 or 4 infections (most commonly COVID-19 and sepsis) reported in 15%.[7] Opportunistic infections and viral reactivations can also occur. Consequently, prophylactic treatment against Pneumocystis jirovecii pneumonia (PJP) and herpes virus is recommended.[13]
• Cytopenias: Reductions in blood cell counts are very common and can be severe. The most frequently reported Grade 3 or 4 laboratory abnormalities include decreased lymphocyte count, decreased neutrophil count (neutropenia), decreased white blood cell count (leukopenia), decreased hemoglobin (anemia), and decreased platelet count (thrombocytopenia).[7] These require regular monitoring of complete blood counts throughout treatment.
• Embryo-Fetal Toxicity: Based on its mechanism of action, epcoritamab may cause fetal harm. Human IgG1 antibodies are known to cross the placenta, and B-cell depletion in a developing fetus could impair its immune system. Therefore, pregnancy testing is required before starting treatment, and female patients of reproductive potential must use effective contraception during treatment and for 4 months after the final dose.[7]

6.3. Common Adverse Events (≥20%)

The most frequently observed adverse events (occurring in ≥20% of patients) across trials, in addition to CRS, are generally constitutional or gastrointestinal in nature. These include fatigue, musculoskeletal pain, injection site reactions, pyrexia (fever), abdominal pain, nausea, and diarrhea.[1] Injection site reactions (e.g., redness, swelling, pain) are very common but are typically low-grade and transient.[7]

Table 3: Incidence and Grading of Key Adverse Reactions (CRS and ICANS) in Pivotal Trials

Adverse Reaction	Indication	Any Grade Incidence	Grade 1	Grade 2	Grade 3	Grade 4/5	Source Snippet(s)
Cytokine Release Syndrome (CRS)	DLBCL/HGBCL	51%	37%	17%	2.5%	0%	19
	Follicular Lymphoma	66%	40%	25%	2%	0%	29
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)	DLBCL/HGBCL	6%	4.5%	1.3%	0%	0.6% (Fatal)	34
	Follicular Lymphoma	6%	3.9%	2.4%	0%	0%	38

VII. Dosage, Administration, and Clinical Management

The administration of epcoritamab is governed by a highly structured protocol designed to maximize safety, particularly by mitigating the risks of CRS and ICANS. The complexity of the dosing, premedication, and monitoring requirements reflects the drug's potent biological activity. This underscores that while epcoritamab is an accessible "off-the-shelf" product, its safe and effective use requires significant institutional expertise, infrastructure, and adherence to established guidelines.

7.1. Recommended Dosing Regimens

Epcoritamab is intended for subcutaneous injection only and must be administered by a qualified healthcare professional with access to medical support for managing severe reactions.[7] The dosing schedule varies by indication, primarily differing in the initial step-up phase in Cycle 1. All treatment cycles are 28 days in length.[7]

• Dosing for R/R DLBCL/HGBCL (2-Step-Up Schedule):
• Cycle 1: Day 1: 0.16 mg; Day 8: 0.8 mg; Day 15: 48 mg (first full dose); Day 22: 48 mg.
• Cycles 2 and 3: 48 mg administered weekly on Days 1, 8, 15, and 22.
• Cycles 4 to 9: 48 mg administered every 2 weeks on Days 1 and 15.
• Cycle 10 and beyond: 48 mg administered every 4 weeks on Day 1.
• Treatment continues until disease progression or unacceptable toxicity.[31]
• Dosing for R/R Follicular Lymphoma (3-Step-Up Schedule): This regimen incorporates an additional, intermediate step-up dose to further reduce the incidence and severity of CRS.[27]
• Cycle 1: Day 1: 0.16 mg; Day 8: 0.8 mg; Day 15: 3 mg; Day 22: 48 mg (first full dose).
• Cycles 2 and 3: 48 mg administered weekly on Days 1, 8, 15, and 22.
• Cycles 4 to 9: 48 mg administered every 2 weeks on Days 1 and 15.
• Cycle 10 and beyond: 48 mg administered every 4 weeks on Day 1.
• Treatment continues until disease progression or unacceptable toxicity.[31]

7.2. Required Clinical Management and Monitoring

Specific monitoring procedures are mandated to ensure patient safety.

• Hospitalization: For patients receiving treatment for the DLBCL/HGBCL indication, hospitalization for 24 hours following the administration of the first full 48 mg dose (Cycle 1, Day 15) is required for close monitoring of CRS and ICANS.[32] This hospitalization is not required for the FL indication when the 3-step-up dosing schedule is used.[38]
• Hydration: It is recommended that all patients be well-hydrated prior to initiating treatment and before each dose, particularly in Cycle 1.[6]

7.3. Premedication and Prophylaxis Protocols

Prophylactic measures are a critical component of the administration protocol to mitigate known risks.

• Cycle 1 Premedication (Mandatory): To reduce the risk of CRS, a three-drug premedication regimen must be administered 30 to 120 minutes before each of the four doses in Cycle 1 for both indications.[17]
• Corticosteroid: Dexamethasone 15 mg (or equivalent, e.g., prednisolone 100 mg) administered orally or intravenously.
• Antihistamine: Diphenhydramine 50 mg (or equivalent) administered orally or intravenously.
• Antipyretic: Acetaminophen 650-1000 mg administered orally.
• Cycle 1 Post-medication: In addition to premedication, patients must also receive dexamethasone 15 mg (or equivalent) for three consecutive days following each of the four doses in Cycle 1.[17]
• Premedication in Subsequent Cycles: If a patient experiences a Grade 2 or 3 CRS event, the full pre- and post-medication regimen should be administered with each subsequent dose until a dose is given without a recurrence of Grade ≥2 CRS.[31]
• Infection Prophylaxis: Given the risk of infection, prophylaxis against Pneumocystis jirovecii pneumonia (PJP) and herpes virus (to prevent zoster reactivation) should be considered as per local guidelines.[13]

7.4. Management of Adverse Reactions and Dose Delays

The prescribing information provides detailed instructions for managing adverse reactions and handling treatment interruptions.

• Dose Modifications: Specific algorithms guide the holding or permanent discontinuation of epcoritamab for Grade ≥2 CRS, any grade of ICANS, severe infections, and clinically significant cytopenias.[17]
• Restarting After a Dose Delay: The protocol for restarting therapy after a missed dose is complex and time-dependent. A delay of more than 8 days after the first step-up dose, or more than 14 days after the second or third step-up dose, necessitates repeating the entire Cycle 1 step-up schedule from the beginning. For a delay of more than 6 weeks (42 days) after any full 48 mg dose, the step-up schedule must also be repeated.[12] This re-priming is a crucial safety measure to prevent a severe immune reaction upon re-exposure after a prolonged break.

Table 4: Indication-Specific Dosing Schedules for Epcoritamab

Cycle	Day(s)	Dose (mg) for DLBCL/HGBCL	Dose (mg) for Follicular Lymphoma	Dosing Frequency
Cycle 1	Day 1	0.16 mg	0.16 mg	Weekly
	Day 8	0.8 mg	0.8 mg
	Day 15	48 mg	3 mg
	Day 22	48 mg	48 mg
Cycles 2-3	Days 1, 8, 15, 22	48 mg	48 mg	Weekly
Cycles 4-9	Days 1, 15	48 mg	48 mg	Every 2 Weeks
Cycles 10+	Day 1	48 mg	48 mg	Every 4 Weeks

VIII. Regulatory and Strategic Landscape

Epcoritamab has navigated a rapid and successful global regulatory pathway, establishing itself as a key therapeutic option in its approved indications. Its strategic positioning is defined by its strong comparative efficacy, manageable safety, and a uniquely convenient administration model that sets it apart from other advanced immunotherapies.

8.1. Global Regulatory Approvals and Designations

Epcoritamab has received approvals from major health authorities worldwide, often through accelerated or conditional pathways that recognize its potential to address significant unmet medical needs.

• United States (Food and Drug Administration - FDA):
• DLBCL Approval: Epcoritamab, under the brand name Epkinly, received its initial FDA approval in May 2023. This was an Accelerated Approval for the treatment of adult patients with R/R DLBCL/HGBCL who have received two or more prior lines of systemic therapy.[1]
• FL Approval: The indication was expanded in June 2024 to include the treatment of adult patients with R/R FL after two or more lines of systemic therapy.[1] This application was also granted Accelerated Approval and benefited from both Priority Review and Breakthrough Therapy designations, underscoring its perceived clinical importance.[1]
• European Union (European Medicines Agency - EMA):
• DLBCL Approval: The European Commission granted conditional marketing authorization for epcoritamab, under the brand name Tepkinly, in September 2023 for the treatment of adults with R/R DLBCL after two or more lines of therapy.[1]
• FL Approval: Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June/July 2024, the EC granted a second conditional marketing authorization in August 2024 for the treatment of R/R FL after at least two prior lines of therapy.[27]
• Orphan Drug Designation: The EMA had previously granted orphan drug designation to epcoritamab in 2022 for both its DLBCL and FL indications, recognizing its potential for treating rare diseases.[1]
• Other Regions: Approvals have also been secured in other key markets, including Canada (December 2023) and Japan.[1]
• Confirmatory Trial Requirement: As these approvals are accelerated or conditional, continued marketing authorization is contingent upon the verification and description of clinical benefit in ongoing confirmatory trials. For the FL indication, the Phase 3 EPCORE FL-2 trial (NCT05409066) is designed to serve this purpose.[8]

8.2. Comparative Analysis: Epcoritamab vs. Other Therapies

The value of epcoritamab is best understood in the context of the existing and emerging therapies for R/R B-cell lymphomas. Its strategic position appears to be a "best of both worlds" approach, aiming to deliver efficacy comparable to the most potent cellular therapies while offering the logistical advantages of an off-the-shelf, subcutaneously administered drug.

8.2.1. Versus Other Bispecific Antibodies (Glofitamab, Mosunetuzumab)

• Efficacy: While direct head-to-head trials are lacking, indirect treatment comparisons provide valuable context. A matching-adjusted indirect comparison (MAIC) between epcoritamab and the intravenous bispecific antibody glofitamab in R/R DLBCL suggested a potential overall survival (OS) benefit for epcoritamab, which became more pronounced after 6 months of treatment. The median duration of complete response (mDoCR) also appeared longer for epcoritamab (36.1 months vs. 26.9 months for glofitamab).[24] In R/R FL, epcoritamab demonstrated numerically higher overall response rates compared to mosunetuzumab and odronextamab.[39]
• Safety: The safety profiles also show potential differences. In R/R FL, one analysis noted that epcoritamab was associated with no Grade ≥3 CRS events, compared to rates of 2.2% for mosunetuzumab and 3.9% for odronextamab. Epcoritamab also had no reported ICANS events of any grade in that comparison.[39]
• Administration Paradigm: This is a major point of differentiation. Epcoritamab is administered subcutaneously and is dosed until disease progression or unacceptable toxicity. In contrast, glofitamab is an intravenous infusion given for a fixed duration of 12 cycles.[41] This difference has profound implications for patient convenience and healthcare resource utilization.

8.2.2. Versus CAR T-Cell Therapy

• Efficacy: Epcoritamab has demonstrated clear efficacy in patients whose disease has progressed after CAR T-cell therapy, defining a critical role in the treatment sequence.[3] Furthermore, indirect comparisons in the third-line or later setting for R/R LBCL found no statistically significant differences in response rates or survival between epcoritamab and CAR T-cell therapy.[43] This positions epcoritamab as an agent with efficacy in the same tier as this highly effective cellular therapy.
• Strategic Positioning: The key advantage of epcoritamab over CAR-T is its "off-the-shelf" nature. It avoids the significant logistical hurdles of CAR-T, which include apheresis, personalized cell manufacturing (which can take several weeks), risk of manufacturing failure, and the need for lymphodepleting chemotherapy.[2] Epcoritamab is immediately available and generally has lower rates of severe CRS and ICANS, making it a potentially safer, faster, and more accessible treatment option for a broader patient population.[25]

8.2.3. Versus Chemoimmunotherapy (CIT) and Other Novel Agents

• Superiority: In the R/R setting, epcoritamab has demonstrated clear superiority over older and some newer standards of care. Indirect comparisons have shown that epcoritamab provides significantly better response rates and overall survival than traditional chemoimmunotherapy, as well as polatuzumab-based regimens and tafasitamab-based regimens, in both 3L+ R/R DLBCL and R/R FL.[39]

8.3. The Value Proposition of Subcutaneous Administration

The subcutaneous route of administration is a cornerstone of epcoritamab's value proposition, offering tangible benefits for patients, providers, and healthcare systems.

• Practice Efficiency: Compared to intravenous therapies like glofitamab, the SC administration of epcoritamab significantly reduces the time required from healthcare personnel (pharmacists, nurses) and, most critically, frees up infusion chair time.[41] One efficiency model estimated that using epcoritamab instead of glofitamab could reduce chair time by 38% per patient over a six-month period.[41]
• Resource Utilization: This improved efficiency translates into substantial resource savings. It can alleviate capacity constraints in busy cancer centers, reduce inpatient monitoring costs compared to both IV bispecifics and CAR-T therapy, and allow for more flexible patient scheduling.[44]
• Patient Convenience: For patients, a quick subcutaneous injection is far more convenient and less burdensome than a lengthy intravenous infusion, improving their quality of life and reducing time spent in the clinic.[39]

Table 5: Indirect Treatment Comparison Highlights in R/R DLBCL

Comparator	Efficacy Outcome	Safety Comparison	Administration/Logistics	Source Snippet(s)
Glofitamab	Potential OS benefit for epcoritamab after 6 months. Longer mDoCR for epcoritamab (36.1 vs 26.9 mo).	Similar AE profiles, but specific rates may differ.	Epcoritamab: SC, treat-to-progression. Glofitamab: IV, fixed duration. Epcoritamab saves significant chair time.	24
CAR T-Cell Therapy	No statistically significant difference in response or survival rates in 3L+ setting.	Generally lower rates of severe CRS and ICANS with epcoritamab.	Epcoritamab: Off-the-shelf, no manufacturing delay. CAR-T: Personalized, requires apheresis, manufacturing, lymphodepletion.	25
Chemoimmunotherapy (CIT)	Significantly better response rates and OS for epcoritamab.	Different toxicity profiles; epcoritamab has unique immune-mediated AEs (CRS/ICANS).	Epcoritamab is a targeted immunotherapy vs. broad cytotoxicity of chemo.	43

IX. Future Directions and Emerging Data

The initial approvals of epcoritamab in the relapsed/refractory setting represent only the first step in a broad and ambitious clinical development strategy. The developers, Genmab and AbbVie, have clearly articulated their goal of establishing epcoritamab as a "core therapy" across the spectrum of B-cell malignancies.[2] This vision is being executed through a comprehensive portfolio of ongoing trials designed to move epcoritamab into earlier lines of treatment, test it in novel combinations, and expand its use to other hematologic cancers.

9.1. Ongoing Phase 3 and Combination Trials: The "Core Therapy" Strategy

The current clinical trial program is systematically evaluating epcoritamab's utility at nearly every major decision point in a lymphoma patient's treatment journey, with the aim of integrating it into the standard of care.

• Combination with Chemoimmunotherapy:
• Salvage Therapy in R/R DLBCL: The EPCORE NHL-2 trial (Arm 10) is investigating epcoritamab in combination with the R-ICE salvage chemotherapy regimen as a bridge to autologous stem cell transplant (ASCT). Preliminary results are highly promising, showing an ORR of 87% and a CR rate of 65%, with 65% of patients successfully proceeding to potentially curative ASCT. This suggests the combination can optimize salvage therapy and improve transplant eligibility.[5]
• Frontline DLBCL: Recognizing the need for better frontline options, trials are underway combining epcoritamab with the standard R-CHOP regimen in newly diagnosed DLBCL, as well as with a less intensive R-miniCVP regimen for older, frail, or anthracycline-ineligible patients.[5]
• Chemotherapy-Free Combinations: A major focus of the development program is to create highly effective, chemotherapy-free regimens.
• Frontline Follicular Lymphoma: The pivotal Phase 3 EPCORE FL-2 trial (NCT06191744) is a head-to-head study comparing epcoritamab plus rituximab and lenalidomide (a combination known as R2) against standard chemoimmunotherapy in patients with previously untreated FL. Positive results from this trial could redefine the frontline standard of care for this disease.[47] Other chemo-free combinations being studied in R/R FL include epcoritamab with the EZH2 inhibitor tazemetostat and with the BTK inhibitor zanubrutinib plus rituximab.[46]
• Frontline DLBCL (Elderly/Unfit): The EPCORE DLBCL-3 trial (NCT05660967) is specifically designed for newly diagnosed elderly patients who are ineligible for standard anthracycline-based chemotherapy. It is evaluating epcoritamab as a monotherapy and in combination with lenalidomide, aiming to provide a tolerable and effective frontline option for this vulnerable population.[49]
• Consolidation and Maintenance Therapy: The role of epcoritamab is also being explored as a consolidation therapy to deepen responses after other treatments. One active trial is comparing epcoritamab to observation in patients who have not achieved a complete remission following CD19-directed CAR T-cell therapy, a setting with a clear unmet need.[46]

9.2. Exploration in Other Hematologic Malignancies

The therapeutic potential of epcoritamab is being investigated beyond DLBCL and FL.

• Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS): The EPCORE CLL-1 trial (NCT04623541) is a significant study evaluating epcoritamab both as a monotherapy and in combination with other targeted agents, such as the BCL-2 inhibitor venetoclax and the BTK inhibitor pirtobrutinib, in patients with R/R CLL and the highly aggressive Richter's Syndrome.[10]
• Other B-Cell Cancers: NCI-supported and other trials are actively recruiting patients to study epcoritamab in other B-cell malignancies, including previously treated Waldenstrom Macroglobulinemia and post-transplant lymphoproliferative disorders (PTLD).[46]

9.3. Concluding Remarks and Expert Outlook

Epcoritamab has unequivocally established itself as a highly effective and transformative therapy for patients with relapsed or refractory DLBCL and FL. Its unique combination of potent, durable efficacy—comparable to that of CAR T-cell therapy—and a convenient, off-the-shelf, subcutaneous administration model gives it a distinct and compelling strategic advantage. The safety profile, while significant, is predictable and has been made more manageable through rational clinical development and optimized administration protocols.

The future of epcoritamab appears exceptionally promising. The extensive ongoing clinical trial program is poised to generate data that could fundamentally reshape treatment paradigms for B-cell malignancies. The key questions now revolve around the outcomes of the large, randomized Phase 3 trials. If epcoritamab-based combinations prove superior to current standards of care in the frontline and second-line settings, it could transition from a valuable late-line therapy to a foundational, core component in the management of a wide array of B-cell cancers, offering a potent, convenient, and potentially chemotherapy-sparing option to a much broader patient population.

Table 6: Overview of Key Ongoing Clinical Trials with Epcoritamab

Trial Name/NCT Number	Phase	Indication/Setting	Combination Agent(s)	Key Question Being Addressed	Source Snippet(s)
EPCORE NHL-2 (Arm 10) (NCT04663347)	1b/2	R/R DLBCL (Salvage)	R-ICE (Rituximab, Ifosfamide, Carboplatin, Etoposide)	Can epcoritamab improve salvage therapy outcomes and bridge more patients to ASCT?	5
EPCORE FL-2 (NCT06191744)	3	Previously Untreated Follicular Lymphoma (1L)	Rituximab + Lenalidomide (R2)	Is epcoritamab + R2 superior to standard chemoimmunotherapy in 1L FL?	47
EPCORE DLBCL-3 (NCT05660967)	2	Newly Diagnosed DLBCL (Elderly/Anthracycline-ineligible, 1L)	Lenalidomide	Can epcoritamab +/- lenalidomide provide an effective frontline chemo-free option for unfit patients?	49
EPCORE CLL-1 (NCT04623541)	1b/2	R/R Chronic Lymphocytic Leukemia (CLL) & Richter's Syndrome	Venetoclax, Pirtobrutinib, Lenalidomide, R-CHOP	What is the safety and efficacy of epcoritamab combinations in CLL and its aggressive transformation?	10
NCT04628494	3	R/R DLBCL	Monotherapy vs. Investigator's Choice Chemo	Can epcoritamab monotherapy demonstrate superiority over standard chemo in a randomized setting?	5
NCT05566621	3	Newly Diagnosed DLBCL (1L)	R-CHOP	Is adding epcoritamab to standard R-CHOP superior to R-CHOP alone for 1L DLBCL?	5
Post-CAR T Consolidation	2	B-cell Lymphoma (not in CR post-CAR-T)	Monotherapy vs. Observation	Can epcoritamab consolidate responses and prevent relapse in patients with residual disease after CAR-T?	46

Works cited

1. Epcoritamab - Wikipedia, accessed August 7, 2025, https://en.wikipedia.org/wiki/Epcoritamab
2. EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Genmab News, accessed August 7, 2025, https://ir.genmab.com/news-releases/news-release-details/epkinlyr-epcoritamab-bysp-approved-us-fda-patients-relapsed-or/
3. Genmab Announces European Commission Approval of TEPKINLY ..., accessed August 7, 2025, https://ir.genmab.com/news-releases/news-release-details/genmab-announces-european-commission-approval-tepkinlyr/
4. Epcoritamab - Orphanet, accessed August 7, 2025, https://www.orpha.net/en/drug/substance/603756
5. Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT), accessed August 7, 2025, https://ir.genmab.com/news-releases/news-release-details/genmab-announces-epcoritamab-investigational-combination-therapy/
6. Epcoritamab - DRUG NAME:, accessed August 7, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Epcoritamab_monograph.pdf
7. Epcoritamab-bysp (subcutaneous route) - Side effects & uses - Mayo Clinic, accessed August 7, 2025, https://www.mayoclinic.org/drugs-supplements/epcoritamab-bysp-subcutaneous-route/description/drg-20551227
8. Epcoritamab-bysp - NCI, accessed August 7, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp
9. Epcoritamab (GEN3013) | Anti-CD3/CD20 Antibody - MedchemExpress.com, accessed August 7, 2025, https://www.medchemexpress.com/epcoritamab.html
10. Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/​Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) - ClinicalTrials.gov, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT04623541
11. Epcoritamab | CAS 2134641-34-0 - AbMole BioScience, accessed August 7, 2025, https://www.abmole.com/products/epcoritamab.html
12. Epcoritamab: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 7, 2025, https://www.drugs.com/epcoritamab.html
13. epcoritamab | Cancer Care Ontario, accessed August 7, 2025, https://www.cancercareontario.ca/en/system/files_force/epcoritamab.pdf?download=1
14. www.cancercareontario.ca, accessed August 7, 2025, https://www.cancercareontario.ca/en/system/files_force/epcoritamab.pdf?download=1#:~:text=B%20%2D%20Mechanism%20of%20Action%20and%20Pharmacokinetics&text=Simultaneous%20engagement%20of%20CD20%2Dexpressing,of%20CD20%2Dexpressing%20B%20cells.&text=Elimination%20Expected%20to%20undergo%20saturable%20target%2Dmediated%20drug%20clearance.
15. Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9827893/
16. Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma - PubMed, accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39708278/
17. EPCO(RAMP) - Cancer Care Ontario, accessed August 7, 2025, https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/75171
18. EMA CHMP Recommends Epcoritamab Conditional Marketing Authorization in Relapsed, Refractory DLBCL | Blood Cancers Today, accessed August 7, 2025, https://www.bloodcancerstoday.com/post/ema-chmp-recommends-conditional-marketing-authorization-for-epcoritamab-in-relapsed-refractory-dlbcl
19. DLBCL Clinical Trial Results - EPKINLY® (epcoritamab-bysp) HCP, accessed August 7, 2025, https://www.epkinlyhcp.com/dlbcl/clinical-trial-results
20. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial - PubMed, accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39322711/
21. 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma - American Society of Hematology, accessed August 7, 2025, https://ashpublications.org/blood/article/144/Supplement%201/4480/533511/3-Year-Update-from-the-Epcore-NHL-1-Trial
22. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). | Journal of Clinical Oncology - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7039
23. Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy. - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7043
24. Paper: Indirect Comparisons of the Efficacy of Epcoritamab Vs ..., accessed August 7, 2025, https://ash.confex.com/ash/2024/webprogram/Paper203994.html
25. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial - PMC - PubMed Central, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11588654/
26. FDA approves EPKINLY® for relapsed or refractory follicular lymphoma, accessed August 7, 2025, https://www.cancerresearch.org/blog/fda-approves-epkinly-for-relapsed-or-refractory-follicular-lymphoma
27. FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed ..., accessed August 7, 2025, https://www.esmo.org/oncology-news/fda-grants-accelerated-approval-to-epcoritamab-bysp-for-relapsed-or-refractory-follicular-lymphoma
28. EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients ..., accessed August 7, 2025, https://ir.genmab.com/news-releases/news-release-details/epkinlyr-epcoritamab-bysp-approved-us-fda-patients-relapsed-or
29. Epcoritamab Produces Promising Responses in Patients With Follicular Lymphoma, accessed August 7, 2025, https://www.bloodcancerstoday.com/post/phase-i-dose-expansion-readout-for-epcoritamab-in-high-risk-follicular-lymphoma
30. Epcoritamab Earns EU Approval in Relapsed/Refractory Follicular Lymphoma, accessed August 7, 2025, https://www.cancernetwork.com/view/epcoritamab-earns-eu-approval-in-relapsed-refractory-follicular-lymphoma
31. Epcoritamab Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 7, 2025, https://www.drugs.com/dosage/epcoritamab.html
32. This label may not be the latest approved by FDA. For current ..., accessed August 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf
33. EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) - Genmab News, accessed August 7, 2025, https://ir.genmab.com/news-releases/news-release-details/epkinlytm-epcoritamab-bysp-approved-us-food-and-drug/
34. FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refracto... - YouTube, accessed August 7, 2025, https://www.youtube.com/watch?v=oM_mG_UdXl0
35. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10115554/
36. Paper: Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1, accessed August 7, 2025, https://ash.confex.com/ash/2023/webprogram/Paper180333.html
37. Pharmacist's Application to Practice: Epcoritamab-bysp | HOPA, accessed August 7, 2025, https://www.hoparx.org/latest-news/pharmacists-application-to-practice-epcoritamab-bysp/
38. dose preparation and administration guide - epkinly® hcp, accessed August 7, 2025, https://www.epkinlyhcp.com/content/dam/epcoritamabhcp/docs/dosing-administration-guide.pdf
39. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma - PMC, accessed August 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12309599/
40. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma | Blood Advances | American Society of Hematology, accessed August 7, 2025, https://ashpublications.org/bloodadvances/article/9/15/3754/537623/Indirect-comparison-of-epcoritamab-vs
41. Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma. | Journal of Clinical Oncology - ASCO Publications, accessed August 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e18919
42. Drawing Comparisons for Relevant Therapies in Patients With DLBCL - Targeted Oncology, accessed August 7, 2025, https://www.targetedonc.com/view/drawing-comparisons-for-relevant-therapies-in-patients-with-dlbcl
43. Comparisons of treatment outcomes of epcoritamab versus ..., accessed August 7, 2025, https://pubmed.ncbi.nlm.nih.gov/39152509/
44. Practice Efficiency Associated with Epcoritamab for the Treatment of ..., accessed August 7, 2025, https://ashpublications.org/blood/article/142/Supplement%201/7254/505081/Practice-Efficiency-Associated-with-Epcoritamab
45. Epcoritamab Plus Chemoimmunotherapy Yields 87% Response ..., accessed August 7, 2025, https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant
46. Clinical Trials Using Epcoritamab - NCI, accessed August 7, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/epcoritamab?pn=1
47. Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma - American Journal of Managed Care, accessed August 7, 2025, https://www.ajmc.com/view/epcoritamab-improves-outcomes-hrqol-in-patients-with-relapsed-refractory-follicular-lymphoma
48. Study Details | Study of Subcutaneous Epcoritamab in Combination ..., accessed August 7, 2025, https://clinicaltrials.gov/study/NCT06191744?term=NCT06191744&rank=1
49. Subcutaneous Epcoritamab With or Without ... - ClinicalTrials.gov, accessed August 7, 2025, https://clinicaltrials.gov/study/NCT05660967